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Changes in oxygen saturation and transcutaneous 
carbon dioxide and oxygen levels in patients 
undergoing fibreoptic bronchoscopy 
E. N. EVANS, K. GANESHALINGAM AND P. EBDEN 
Patients undergoing bronchoscopy are usually monitored with pulse oximetry to measure arterial oxygen saturation, 
but this can fail to detect hypoventilation, particularly if added inspired oxygen is used. Transcutaneous oxygen and 
carbon dioxide tensions can be measured; the later reflecting respiratory drive. We compared transcutaneous PO, 
and PCO, values with oxygen saturation in patients undergoing day-case bronchoscopy, to see if this information 
would further improve the safety of the bronchoscopic procedure. 
Twenty-two consecutive patients undergoing routine fibreoptic bronchoscopy (15 male, mean age 62.3 years; 
range 45-82 years), were studied using pulse oximetry (OXImeter, Radiometer) and transcutaneous PCOJPO, 
monitoring (TCM3, TINA, Radiometer). 
We documented a statistically significant increase in transcutaneous PCO, from mean (SD) stable baseline levels 
of 5.8 (0.3) kPa (range 4.2-7.9 kPa) to mean peak levels during bronchoscopy of 7.0 (1.0) kPa (range 5.0-X.7 kPa). 
The time to first adverse change in transcutaneous PCO, (P~O.046) and PO, (P=O.O35) occurred more rapidly than 
reduction in oxygen saturation in 19 of the 22 cases; median times for change in PCO, of 67 s (range lo-1800 s), PO, 
of 120 s (range 266559 s) and oxygen saturation of 174 s (range 43-1332 s), timed from administration of i.v. 
sedation prior to each bronchoscopy. 
Transcutaneous PCOJPO, monitoring during fibreoptic bronchoscopy provided evidence of hypoventilation 
with significantly elevated levels of transcutaneous PCO,. This method of monitoring provides an earlier indication 
of respiratory depression during fibreoptic bronchoscopy compared with pulse oximetry. 
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Introduction 
Fibreoptic bronchoscopy (FOB) is a common invasive 
pulmonary investigation providing direct visualization of 
the bronchial tree as far as the subsegmental bronchi, 
allowing diagnostic samples to be taken. FOB is a safe 
procedure with a complication rate of approximately 0.1%. 
Exclusion criteria include central cyanosis at rest, breath- 
lessness, poorly controlled angina and recent myocardial 
infarction. Patients with a low FEV, (‘1 1) can be safely 
examined but sedation is usually withheld. 
Introduction of the fibreoptic bronchoscope into the 
airways results in partial airway obstruction and reductions 
in oxygen saturation, measured by pulse oximetry, are 
recognized in patients undergoing endoscopic procedures 
using benzodiazepines and narcotics for sedation (l-3). 
Patients are usually monitored by clinical observation and 
with pulse oximetry (monitoring adequacy of arterial oxy- 
genation) and supplemental oxygen is given via nasal 
cannulae. Failure of pulse oximetry to detect intra- and 
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post-operative hypoventilation is recognized, especially 
with a high inspired oxygen concentration (4,5) and marked 
hypoxaemia is sometimes difficult to detect clinically (6). 
Elevated values of PaCO, are a better guide to type II 
respiratory failure secondary to alveolar hypoventilation, 
which is the mechanism induced by the procedure of FOB 
and/or the sedation. 
Transcutaneous PCOJPO, monitoring was introduced 
in the early 1980s using the principle that if an area of skin 
is warmed to 44°C dissolved gases diffuse through the skin. 
This technique is now widely used by anaesthetists in the 
operating theatre and on Intensive Care and Special Care 
Baby Units in the assessment of gas tensions in high-risk 
situations (7,X). 
A literature search using Medline (key words: carbon 
dioxide, transcutaneous and bronchoscopy) was unable to 
find any previous studies on the use of transcutaneous 
PCO,/PO, monitoring during FOB. We wished to assess 
if transcutaneous PCOJPO, monitoring provided any 
additional information during routine FOB in adults, as 
compared with pulse oximetry. 
Methods 
Twenty-two consecutive patients undergoing routine FOB 
(15 male, mean age 62.3 years; range 45582 years) were 
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entered into the study. The patients were examined clini- 
cally and underwent routine chest X-ray, spirometry, 
arterial blood gas analysis and electrocardiogram (ECG), 
before being considered as suitable for the procedure. 
Spirometry demonstrated mean values of FEV, (SD) of 61.8 
(20.1)% and FVC 74.1 (23.1)% (results expressed as per- 
centages of predicted values) with FEV,/FVC of 66.3 
(13.0)%. Monitoring of the patients using finger clip pulse 
oximetry (OXImeter, Radiometer) and transcutaneous 
PCOJPO, electrodes (TCM3, TINA, Radiometer) was 
performed from 1 h prior to FOB for a total of 4 h. 
Atropine (mean dose 0.59 mg; range 0.30-0.60 mg) and 
Papaveratum (Omnopona, mean dose 9.43 mg; range 
2.50-10.0 mg) were administered intramuscularly 30 min 
before the FOB with the doses modified on the basis of the 
clinical condition of the patient and results of spirometry. 
Patients took their maintenance treatment 4 h prior to the 
FOB, which in four patients included the use of inhaled 
bronchodilators. Patients were administered oxygen at a 
rate of 2 llmin via nasal cannulae and the procedure was 
initiated when a stable trace was obtained in the values of 
oxygen saturation and transcutaneous PCOJPO,. Altera- 
tions in supplemental oxygen were made according to 
clinical need and to maintain the oxygen saturation above 
90%. Intravenous diazepam suspension (Diazemuls; 
diazepam 10 mg12 ml), administered through an indwelling 
iv. catheter, was given at the beginning of the procedure to 
induce light sedation and throughout the bronchoscopy 
to keep the patient comfortable (mean total dose 
7.60 mg; range 2.50-20.0 mg). Topical anaesthesia of the 
oropharynx and pharynx was obtained by spraying with 
xylocaine (2%). 
The fibreoptic bronchoscope (Olympus BF20D) was 
passed orally under direct vision with the patient supine. 
Laryngeal and endobronchial anaesthesia was obtained by 
placing lignocaine 2% (mean dose 17.1 ml; range 6.0- 
26.0 ml) topically through the bronchoscope. Broncho- 
scopic washings were performed by passing 20 ml aliquots 
of normal saline through the bronchoscope with biopsies 
taken from lesions seen in the major airways. During the 
FOBS patients were also monitored continuously with 
ECG. 
Prior to each investigation a new electrode membrane 
and electrolyte solution was applied and the transcutaneous 
PCO,IPO, monitors were calibrated against a standard 
concentration compressed gas (consisting of 5.0% carbon 
dioxide, 20.9% oxygen, 74.1% nitrogen), via the TCC3 
Calibration Unit provided by Radiometer, as outlined by 
the manufacturer. The transcutaneous electrodes were 
attached to the patient by an adhesive ring, over the 
pectoral region, with the temperature set at 44°C. The 
area was shaved (if necessary), minimally abraded and 
cleaned with alcohol. The 90% response times for the 
transcutaneous PCO, electrode was 50 s and for the PO, 
electrode 20 s, with continuous sampling. 
The pulse oximeter’s response time was 2 s with weighted 
average sampling every 6 s. Both the oximeter and the 
transcutaneous monitor printed their information using 
compact digital recorders by Radiometer, which provided 
real time recordings. The results of transcutaneous PCO,I 
TABLE 1. Stable pre-bronchoscopy transcutaneous and 
arterial blood gas tensions 
TcPO, 8.6 (2.5) kPa Arterial PO, 10.7 (3.5) kPa 
TcPCO, 5.8 (0.8) kPa Arterial PCO, 5.3 (0.6) kPa 
SPO, 93.6 (3.0) % SaO, 94.2 (3.0) % 
Values expressed as means with standard deviations in 
parenthesis. 
Tc, transcutaneous. SaO,, arterial haemoglobin saturation. 
SpOZ, pulse oximetry estimation of SaO,. 
PO, values were ‘blinded’ from the physician performing 
the FOB. 
Ethical approval was provided by the local ethics com- 
mittee and all patients gave written informed consent prior 
to the study. 
Results 
All subjects underwent uncomplicated FOB without any 
serious side-effects, with no patients requiring reversal of 
their sedation. The median duration of each FOB was 703 s 
(range 250-885 s) with 20 patients undergoing bronchial 
washings, 10 in combination with biopsy. All subjects 
received supplemental oxygen at rates varying between 
2210 l/min via nasal cannulae. 
Mean stable values of transcutaneous PCO, and PO, at 
rest prior to FOB were 5.8 (0.8) kPa and 8.6 (2.5) kPa 
respectively, with mean oxygen saturation (SpO,) of 93.6 
(3.0)%. Corresponding mean arterial blood gas values of 
PaCO,, PaO, and oxygen saturation (SaO,) were 5.3 (0.6) 
kPa, IO.7 (3.5) kPa and 94.2 (3.0)% respectively (Table 1). 
The FOBS were performed after a steady trace was 
obtained on both transcutaneous and pulse oximeter 
recordings, following the initial administration of oxygen. 
All events were timed from the first bolus injection of 
diazepam suspension, which was taken as time zero. 
The median time for the bronchoscope to be passed into 
the trachea for the 22 patients was 185 s (range 855400 s) 
with median time to the first increase in transcutaneous 
PCO, (0.3 kPa or more) being 67 s (range lo-1800 s) fol- 
lowing the diazepam. The median time to first reduction in 
transcutaneous PO, (0.3 kPa or more) was 120 s (range 
26-560 s) and median time for the first reduction in oxygen 
saturation (2% or more) was 174 s (range 43-1332 s) (Table 
2). The levels of transcutaneous PO, and PCO, deterio- 
rated more rapidly from baseline than corresponding oxy- 
gen saturations in 19 out of the 22 cases, with P-values of 
0.035 and 0.046 respectively (independent samples t-test). 
The mean peak value of transcutaneous PCO, was 7.0 
(1 .O) kPa with a mean difference in this peak compared with 
resting values of 1.3 (0.7) kPa. This difference is statistically 
significant with a P-value of <O.OOl (Student’s paired t-test; 
Table 3). It took a median time of 372 s (range 6775940 s), 
for the transcutaneous PCO, to reach its peak and a 
median time of 951 s (range 2664440 s) to return to 
baseline levels. The varying flow rates of inspired oxy- 
gen, given in response to clinical need and/or oxygen 
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TABLE 2. Timing of events for the 22 patients 
Median time (range) 
Time to first reduction, 2% from baseline, in SpO, 174 (4331332) s 
Time to first reduction, 0.4 kPa from baseline, in TcPO, 120 (266560) s* 
Time to first increase, 0.4 kPa from baseline, in TcPCO, 67 (10-1800) s” 
Time to maximum increase in TcPCO, 372 (6775940) s 
Time for TcPCO, return to baseline 951 (266-4440) s 
Time to introduction of bronchoscope into the trachea 185 (85400) s 
Duration of bronchoscopy 703 (250-885) s 
Time zero is taken as the time of administration of i.v. diazepam suspension. 
*Statistically significant when compared with the time to the first reduction in SpOZ, using the 
independent samples t-test. 
desaturation, do not permit further interpretation of the 
transcutaneous PO, or oxygen saturation results. 
The design of our study did not allow us to draw any 
conclusions about the increase in transcutaneous PCO, 
with diazepam dose, as the dosage was equated to the 
clinical need of the patient and not given incrementally. 
There was no statistical correlation between the increase in 
transcutaneous PCO, and the duration of the FOB or the 
values of FEV, used as independent variables. 
Discussion 
We found a significant increase in transcutaneous PCO, in 
patients undergoing FOB. This increase in transcutaneous 
PCO, occurred against a varying concentration of 
inspired oxygen, administered in response to reduced 
oxygen saturation and the patient’s clinical need. The 
increase in transcutaneous PCO, implies alveolar hypo- 
ventilation induced by FOB with the combination of i.v. 
sedation, underlying lung disease and the insertion of the 
bronchoscope into the major airways. 
We observed the time taken to the first reduction in 
transcutaneous PO, and the first increase in transcutaneous 
PCO, (a change of at least 0.3 kPa from a steady baseline 
with the administration of supplemental oxygen via nasal 
cannulae) was quicker than the first reduction in oxygen 
saturation (at least 2% from baseline), in 19 of the 22 cases. 
This can be partly explained by extrapolation from the 
oxygen dissociation curve. In patients receiving supplemen- 
TABLE 3. Transcutaneous PCO, values 
Mean value 
(SD) 
Pre-bronchoscopy (a) 5.8 (0.8) kPa 
Maximum value during bronchoscopy (b) 7.0 (1.0) kPa 
Difference between (a) and (b) 1.3 (0.7) kPa* 
*Statistically significant using Student’s paired t-test. 
tal oxygen via nasal cannulae an inspired oxygen concen- 
tration of up to 68% can be generated if the patient is 
hypoventilating (9) which will increase the PaO, to greater 
than 13.3 kPa. With further hypoventilation the reduction 
in PaO, will need to be large to reduce the SpOZ, because of 
the sigmoid shape of the oxygen dissociation curve. The 
more rapid reduction in transcutaneous PO, than SpO, is 
made more interesting in view of the fact that the response 
times for the TCM3 transcutaneous PCOJPO, monitor are 
slower than the corresponding times for the OXImeter. 
When comparing the changes in oxygen saturation and 
transcutaneous PCO,IO, with the time taken to introduce 
the bronchoscope into the trachea and the duration of the 
bronchoscopy, it can be seen that many of these changes 
either precede or follow the brochoscopic procedure. 
Changes preceding the presence of the bronchoscope in the 
major airways can be explained by the effects of sedation in 
patients with underlying airways disease. The changes in 
oxygen saturation and transcutaneous PCO,/O, following 
the procedure is due to the sedation having a half-life 
greater than the duration of the bronchoscopy and the 
cessation of the sympathetic drive caused by the presence of 
the bronchoscope within the airways. 
Fibreoptic bronchoscopy (FOB) is a safe, established 
technique but patients undergoing FOB are at risk of type 
II respiratory failure. Sedation can cause hypoventilation 
during endoscopic procedures secondary to central respir- 
atory depression (1,2) and this can be aggravated in FOB 
by the introduction of the bronchoscope into the major 
airways, leading to a reduction in the cross-sectional area 
with an increase in resistance to airflow. This is in contrast 
to patients undergoing upper gastrointestinal endoscopy, in 
whom the presence of the endoscope does not appear to 
contribute to the airway obstruction or endoscope-induced 
CO, retention (10). Patients investigated for suspected 
lung cancer often have smoking-related obstructive airways 
disease which further increases the risk of procedural 
complications, but careful assessment can exclude patients 
at high risk. 
Patients undergoing FOB are usually monitored with 
pulse oximetry. Maranetra (3) documented a reduction in 
oxygen saturation of l-25% (mean 5.6%) in 97 out of 100 
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patients undergoing FOB. Despite this, recent papers (45) 
have questioned the reliability of pulse oximetry as a 
monitoring technique in the presence of high inspired 
oxygen concentrations. Oximetry measures the oxygenation 
of blood and will detect hypoxaemia, it can not detect 
hypercapnia and therefore the adequacy of ventilation. 
Alveolar hypoventilation, produced by sedation during 
FOB, leads to a rise in alveolar and arterial carbon dioxide 
tension and a reduction in alveolar oxygen tension with 
resultant hypoxaemia. When breathing room air the oxygen 
saturation will fall rapidly, giving a good indication of 
ventilatory status, but when the patient is receiving supple- 
mental oxygen the alveolar PCO, will have to rise further 
to cause hypoxaemia which will result in significant 
desaturation. 
In our study we used transcutaneous PCO,IPO, values to 
monitor respiratory status in patients undergoing FOB. 
Transcutaneous gas electrodes work on the principle that 
elevation of skin temperature (usually to 44°C) makes the 
skin permeable to gas diffusion by dissolving the lipid 
structure of dead, keratinized cells. This heating also 
increases cutaneous blood flow, arterializes the capillary 
blood and results in a shift in the oxygen dissociation curve 
to the right which amounts to a c. 6% increase in PO, per 
“C. This increase is offset by diffusion of oxygen out of 
the capillary loops and uptake of oxygen by,metabolically 
active cells. In the measurement of transcutaneous 
PCO, the increase in temperature increases the PCO, in 
blood by c. 4.8% per “C and CO, is also produced by 
living cells. These factors result in transcutaneous levels of 
PCO, being greater and PO, being lower than the corre- 
sponding arterial levels. These principles are based upon 
haemodynamically stable subjects with adequate skin 
perfusion. 
The TCM3 transcutaneous PCO,IPO, electrode com- 
bines a Clark-type 0, electrode and a Severinghaus-type 
CO, electrode. The 0, electrode produces a current directly 
proportional to the 0, concentration against the outer 
membrane. The CO, electrode measures a voltage gener- 
ated by hydrogen ions produced after the CO, diffuses 
across the membrane to produce hydrogen and bicarbonate 
ions. Prior to use the electrodes must be calibrated against 
a gas of fixed concentration (one-point calibration uses 5% 
CO,/20.9% 0, or two point calibration 10% CO,/90% N2). 
Transcutaneous levels of PO, and X0, are valid in their 
own right; they do not correspond directly to the arterial 
values but can reflect change in arterial gas tensions. There 
are no normal ranges for transcutaneous measurements and 
our calculations and conclusions are based on the observed 
trends in transcutaneous PCO,IPO,. 
The advantages of transcutaneous monitoring are the 
direct measurement of transcutaneous PCO, and PO, 
(important with high inspired oxygen concentrations) and a 
rapid response time. The disadvantages are that the pro- 
cedure is time-consuming, requiring calibration, a ‘warm- 
up’ period and electrode repositioning at 4 h due to drift 
from the calibrated baseline. As with oximetry, transcu- 
taneous monitoring requires good skin perfusion and it is 
not known if the potential thermal damage and oedema 
caused by the electrode affects sensitivity and response time. 
Data calibrating transcutaneous values against arterial 
blood samples are based on studies with neonates and it is 
not known how transcutaneous monitoring compares 
in adults, disease states, anxiety and in response to 
medication. 
This study highlights the limitations of pulse oximetry in 
detecting respiratory failure in patients undergoing fibre- 
optic bronchoscopy who are receiving supplemental 
oxygen. This problem can be overcome by using a transcu- 
taneous PCO,IPO, monitor to assess the patient’s respira- 
tory status during the FOB. The clinical relevance of 
transcutaneous PCO,IPO, monitoring during FOB over 
clinical observation and pulse oximetry is uncertain as in 
this study no further adverse events were prevented by this 
monitoring, but no patients in this study were severely 
compromised or required reversal of their sedation. This 
study has not changed our clinical practice in that we 
continue to use pulse oximetry to monitor patients during 
bronchoscopy, rather than the more complex transcu- 
taneous PCO, analysis, but we are aware of the limitations 
of oximetry and place greater emphasis on clinical evidence 
of hypoventilation. 
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